Brian M Alexander
Overview
Explore the profile of Brian M Alexander including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
158
Citations
6035
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Shroff R, Goodman K, Mehnert J, Vose J, Moran S, Yessaian J, et al.
J Clin Oncol
. 2022 Nov;
41(9):1659-1663.
PMID: 36331246
No abstract available.
12.
Nesteryuk V, Hamdani O, Gong R, Almog N, Alexander B, Soosman S, et al.
Clin Lung Cancer
. 2022 Oct;
23(8):e550-e555.
PMID: 36253270
This case signifies the importance of obtaining tumor comprehensive genomic profiling (CGP) as it has utility in cancer type classification and helping in diagnosing recurrence/metastasis or separately occurring primary tumors....
13.
Ventz S, Khozin S, Louv B, Sands J, Wen P, Rahman R, et al.
Nat Commun
. 2022 Oct;
13(1):5783.
PMID: 36184621
Patient-level data from completed clinical studies or electronic health records can be used in the design and analysis of clinical trials. However, these external data can bias the evaluation of...
14.
Graf R, Fisher V, Weberpals J, Gjoerup O, Tierno M, Huang R, et al.
JAMA Netw Open
. 2022 Mar;
5(3):e225394.
PMID: 35357449
Importance: The most useful biomarkers for clinical decision-making identify patients likely to have improved outcomes with one treatment vs another. Objective: To evaluate treatment class-specific outcomes of patients receiving immune...
15.
Plana D, Fell G, Alexander B, Palmer A, Sorger P
Nat Commun
. 2022 Feb;
13(1):873.
PMID: 35169116
Individual participant data (IPD) from oncology clinical trials is invaluable for identifying factors that influence trial success and failure, improving trial design and interpretation, and comparing pre-clinical studies to clinical...
16.
Williams E, Montesion M, Lincoln V, Tse J, Hiemenz M, Mata D, et al.
Am J Surg Pathol
. 2022 Jan;
46(6):729-741.
PMID: 35034043
Inactivating mutations in tumor suppressor genes TP53 and RB1 are considered central drivers in leiomyosarcomas (LMSs). In high-risk human papillomavirus (HPV)-related tumors, a similar functional outcome is achieved through oncoproteins...
17.
Rahman R, Ventz S, McDunn J, Louv B, Reyes-Rivera I, Polley M, et al.
Lancet Oncol
. 2021 Sep;
22(10):e456-e465.
PMID: 34592195
Integration of external control data, with patient-level information, in clinical trials has the potential to accelerate the development of new treatments in neuro-oncology by contextualising single-arm studies and improving decision...
18.
Driver J, Hoffman S, Tavakol S, Woodward E, Maury E, Bhave V, et al.
Neuro Oncol
. 2021 Sep;
24(5):796-808.
PMID: 34508644
Background: Meningiomas are the most common primary intracranial tumor in adults. Clinical care is currently guided by the World Health Organization (WHO) grade assigned to meningiomas, a 3-tiered grading system...
19.
Lee J, Madison R, Classon A, Gjoerup O, Rosenzweig M, Frampton G, et al.
JCO Precis Oncol
. 2021 Sep;
5.
PMID: 34476332
Purpose: exon 14 (ex14) skipping alterations are oncogenic drivers in non-small-cell lung cancer (NSCLC). We present a comprehensive overview of ex14 samples from 1,592 patients with NSCLC, associated clinicogenomic characteristics,...
20.
Murugesan K, Sharaf R, Montesion M, Moore J, Pao J, Pavlick D, et al.
JCO Precis Oncol
. 2021 Sep;
5.
PMID: 34476330
Purpose: Combined hepatocellular cholangiocarcinoma (cHCC-CCA) is a rare, aggressive primary liver carcinoma, with morphologic features of both hepatocellular carcinomas (HCC) and liver cholangiocarcinomas (CCA). Methods: The genomic profiles of 4,975...